The active compound in the best-selling drug Ozempic markedly lowers the risk of complications from chronic kidney disease, according to a multiyear study published Friday — a finding that could ...

(Bloomberg) -- Novo Nordisk A/S’s blockbuster diabetes drug Ozempic cut patients’ risk of dying in a kidney-disease study, the latest research pointing to the medicine’s usefulness in a ...

Novo Nordisk's GLP-1 agonist Ozempic has become the first drug in the class to be approved by the FDA to reduce the risk of worsening kidney disease in people with type 2 diabetes. The approval ...

Semaglutide, available under the brand names Ozempic and Wegovy, may help decrease the risk of major adverse cardiovascular ...

Share on Pinterest Recent anecdotal reports have highlighted strange side effects of GLP-1 medications used for weight loss like “Ozempic ... health lowering kidney disease risk improving ...

Ozempic is already approved to treat T2D, for cardiovascular risk reduction ... worsening kidney disease and cardiovascular death in people with T2D and CKD. …as Rybelsus cuts MACE in type ...

A new study suggests that semaglutide, the active ingredient in Ozempic, may help decrease liver fat, inflammation, and ...

If you don’t take care of your kidneys, you risk a slew of health problems, some of which could cause the organs to shut down altogether. Kidney disease ... Jardiance and Ozempic, were approved ...

GLP-1 drugs like Ozempic and Wegovy have been linked ... “We already know bariatric surgery cuts obesity-related cancer risk by about a third; these data suggest target GLP-1s may cut that ...

The announcement follows new research that suggested drugs like Wegovy, Mounjaro and Ozempic slashed the risk of contracting the disease. Scientists from Israel said the drugs, also known as GLP ...

The cutting-edge weight-loss drug Ozempic/Wegovy can stop and even reverse fatty liver disease, a new clinical trial has found. Nearly twice as many people taking semaglutide stopped their fatty ...